MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final beta user experience which took place during the first quarter in both the U.S. and Germany," said Dr. Joseph V. Gulfo, President and CEO of MELA Sciences. "We are pleased to be transitioning from beta to a controlled and deliberate commercial launch of MelaFind, which will be focused predominantly in the Northeastern United States and in several key cities throughout Germany." "We will work with our customers to train and assist them in using MelaFind appropriately and to incorporate its use successfully into their practices. We believe that this approach is best suited for a first-of-its-kind breakthrough product in order to provide a strong platform for a more widespread dissemination of MelaFind in the future."